Implementing innovative RWE strategies carries some challenges, but not doing so very likely carries greater risk than reward. Depending on the disease, therapy, or target patient group, some payers may continue to be hesitant to engage in access agreements irrespective of the promise of RWE generation, and some providers may continue to be reluctant to adopt these new treatment options.
Our experts share how real-world evidence (RWE) can be leveraged to help offset economic uncertainties, facilitate access, and create a sustainable foundation for long-term data generation for cell and gene therapies.
By Youbean Oak, Zachary Kleiman, and Samantha Cambray, GuidehouseThis byline originally appeared in Cell & Gene.
Complexity demands a trusted guide with the unique expertise and cross-sector versatility to deliver unwavering success. We work with organizations across regulated commercial and public sectors to catalyze transformation and pioneer new directions for the future.